Saeid Najafi Fard1, Ivan Schietroma2, Giuseppe Corano Scheri2, Noemi Giustini2, Sara Serafino2, Eugenio Nelson Cavallari2, Claudia Pinacchio2, Gabriella De Girolamo2, Giancarlo Ceccarelli3, Carolina Scagnolari4, Vincenzo Vullo2, Gabriella d'Ettorre3. 1. Department of public health and infectious diseases, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: saeid.najafifard@gmail.com. 2. Department of public health and infectious diseases, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy. 3. Department of public health and infectious diseases, Azienda Policlinico Umberto I of Rome, Rome, Italy. 4. Laboratory of Virology, Affiliated to Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Abstract
AIM: Chronic immune activation and poor T-cell immune response are strongly associated with disease progression and pathogenesis of both hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1 infections. Little is known about the impact of anti-HCV Interferon (IFN)-free direct-acting antiviral (DAA) therapy on the systemic T-cells activation and patterns of peripheral T-cells producing pro-inflammatory cytokines. PATIENTS AND METHODS: Forty-five subjects including 18 HCV mono-infected, 17 HCV/HIV-1 co-infected patients under antiretroviral therapy (ART), and 10 healthy controls (HCs) were recruited. Blood samples were collected at baseline (T0) and 12 weeks after the end of DAA therapy (T1). Cell phenotypes (CD3, CD4, CD8), activation markers (CD38 and HLA-DR), and frequency of IFN-γ, interleukin (IL)-17, and IL-22 producing CD4+ and CD8+ T-cells were measured by flow cytometry. Plasma levels of related cytokines were also measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Both HCV, and HCV/HIV-1 patients before and after therapy, showed significant higher percentages of any T-cell subset expressing CD38 and/or HLA-DR compared to HCs. No differences were observed in T-cells activation at T1 compared to T0 in patient groups, and when HCV patients were compared to HCV/HIV-1 group (P>0.05). After therapy, the potential of total circulating T helper (Th) and T cytotoxic (Tc) cells producing IFN-γ, IL-17, and IL-22 were increased. Plasma level of IFN-γ at baseline was showed difference compared to HCs, and significantly reduced after therapy (P<0.05). CONCLUSION: Total T-cells immune response enhances after therapy, however, the state of immune activation may remain elevated for a longtime after the end of treatment and contribute to post-Sustained Virologic Response (SVR) consequences.
AIM: Chronic immune activation and poor T-cell immune response are strongly associated with disease progression and pathogenesis of both hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1 infections. Little is known about the impact of anti-HCV Interferon (IFN)-free direct-acting antiviral (DAA) therapy on the systemic T-cells activation and patterns of peripheral T-cells producing pro-inflammatory cytokines. PATIENTS AND METHODS: Forty-five subjects including 18 HCV mono-infected, 17 HCV/HIV-1 co-infectedpatients under antiretroviral therapy (ART), and 10 healthy controls (HCs) were recruited. Blood samples were collected at baseline (T0) and 12 weeks after the end of DAA therapy (T1). Cell phenotypes (CD3, CD4, CD8), activation markers (CD38 and HLA-DR), and frequency of IFN-γ, interleukin (IL)-17, and IL-22 producing CD4+ and CD8+ T-cells were measured by flow cytometry. Plasma levels of related cytokines were also measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Both HCV, and HCV/HIV-1patients before and after therapy, showed significant higher percentages of any T-cell subset expressing CD38 and/or HLA-DR compared to HCs. No differences were observed in T-cells activation at T1 compared to T0 in patient groups, and when HCVpatients were compared to HCV/HIV-1 group (P>0.05). After therapy, the potential of total circulating T helper (Th) and T cytotoxic (Tc) cells producing IFN-γ, IL-17, and IL-22 were increased. Plasma level of IFN-γ at baseline was showed difference compared to HCs, and significantly reduced after therapy (P<0.05). CONCLUSION: Total T-cells immune response enhances after therapy, however, the state of immune activation may remain elevated for a longtime after the end of treatment and contribute to post-Sustained Virologic Response (SVR) consequences.
Authors: Nicole E Skinner; Candelaria Vergara; Ramy El-Diwany; Harry Paul; Alyza Skaist; Sarah J Wheelan; David L Thomas; Stuart C Ray; Ashwin Balagopal; Justin R Bailey Journal: Viral Immunol Date: 2021-10-21 Impact factor: 2.175
Authors: Ann W N Auma; Carey Shive; Sofi Damjanovska; Corinne Kowal; Daniel E Cohen; Debika Bhattacharya; Beverly Alston-Smith; Melissa Osborne; Robert Kalayjian; Ashwin Balagopal; Mark Sulkowski; David Wyles; Donald D Anthony Journal: Open Forum Infect Dis Date: 2021-02-18 Impact factor: 4.423
Authors: Xia Wu; Jessica B Roberto; Allison Knupp; Alexander L Greninger; Camtu D Truong; Nicole Hollingshead; Heidi L Kenerson; Marianne Tuefferd; Antony Chen; David M Koelle; Helen Horton; Keith R Jerome; Stephen J Polyak; Raymond S Yeung; Ian N Crispe Journal: Front Immunol Date: 2022-03-09 Impact factor: 7.561